TrialThe Lancet. Oncology2020

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.

Aleix Prat et al.PubMed ↗Publisher ↗

No numbers read from the abstract.